The stock price of Pyxis Oncology Inc (NASDAQ: PYXS) has jumped by 12.37 compared to previous close of 3.94. Despite this, the company has seen a gain of 17.75% in its stock price over the last five trading days. prnewswire.com reported 2024-09-25 that NEW YORK, Sept. 25, 2024 /PRNewswire/ — Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty.
Is It Worth Investing in Pyxis Oncology Inc (NASDAQ: PYXS) Right Now?
Moreover, the 36-month beta value for PYXS is 1.30. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PYXS is 46.81M and currently, short sellers hold a 10.49% of that float. On November 08, 2024, PYXS’s average trading volume was 479.70K shares.
PYXS’s Market Performance
The stock of Pyxis Oncology Inc (PYXS) has seen a 17.75% increase in the past week, with a 40.33% rise in the past month, and a 31.38% gain in the past quarter. The volatility ratio for the week is 5.53%, and the volatility levels for the past 30 days are at 6.79% for PYXS. The simple moving average for the past 20 days is 20.09% for PYXS’s stock, with a 9.49% simple moving average for the past 200 days.
Analysts’ Opinion of PYXS
Stifel, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $10. The rating they have provided for PYXS stocks is “Buy” according to the report published on August 08th, 2024.
Jefferies gave a rating of “Buy” to PYXS, setting the target price at $10 in the report published on May 07th of the current year.
PYXS Trading at 22.88% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.37% of loss for the given period.
Volatility was left at 6.79%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares surge +33.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.03% upper at present.
During the last 5 trading sessions, PYXS rose by +14.89%, which changed the moving average for the period of 200-days by +36.71% in comparison to the 20-day moving average, which settled at $3.68. In addition, Pyxis Oncology Inc saw 145.97% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PYXS
Current profitability levels for the company are sitting at:
- -3.51 for the present operating margin
- 0.82 for the gross margin
The net margin for Pyxis Oncology Inc stands at -3.03. The total capital return value is set at -0.36. Equity return is now at value -37.58, with -30.87 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.71. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -40.19.
Currently, EBITDA for the company is -78.49 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 12.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.53.
Conclusion
To wrap up, the performance of Pyxis Oncology Inc (PYXS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
